Drug Information

Drug General Information
Drug ID
D0F5MT
Former ID
DAP000707
Drug Name
Fosamprenavir
Synonyms
Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Approved [550326]
Therapeutic Class
Anti-HIV Agents
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL
Formula
C25H36N3O9PS
Canonical SMILES
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=<br />O)(=O)C3=CC=C(C=C3)N
InChI
1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
InChIKey
MLBVMOWEQCZNCC-OEMFJLHTSA-N
CAS Number
CAS 226700-79-4
PubChem Compound ID
131536
PubChem Substance ID
630866, 10242897, 14764609, 14911487, 17396671, 29309884, 46504901, 50070552, 50071323, 75335910, 103633149, 104375333, 126680953, 134222910, 134337996, 135111213, 136139133, 137006000, 142147341, 160964617, 175267520, 179296052, 210279023, 223447627, 223664897, 226420602, 251971352
SuperDrug ATC ID
J05AE07
SuperDrug CAS ID
cas=226700794
Target and Pathway
Target(s) HIV protease Target Info Inhibitor [537453]
References
Ref 550326Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
Ref 537453Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Antimicrob Chemother. 2009 Aug;64(2):398-410. Epub 2009 Jun 10.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.